EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Salivary Gland Uptake on 18 F‐Florbetaben PET Did Not Demonstrate Additional Diagnostic Value for Alzheimer's Disease

Hyun Woo Kwon, Saim Jung, Cheolmin Shin, Jong Hun Kim, Moon Ho Park

Brain and Behavior · 2026

DOI: 10.1002/brb3.71199 ↗

At a glance

Journal article in Brain and Behavior, 2026. Written by Hyun Woo Kwon and 4 co-authors. Institution: Department of Nuclear Medicine, Korea University Ansan Hospital, Ansan, South Korea. Major MEDLINE topics: Alzheimer Disease, Positron-Emission Tomography, Stilbenes, Aniline Compounds. Cited 1 times so far (Crossref); 49 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objectives

Saliva, like other body fluids, has been investigated as a source of biomarkers for Alzheimer's disease (AD) due to its accessibility. Recently, decreased amyloid‐PET uptake in the salivary glands of patients with AD was reported, prompting interest in the potential clinical relevance of that finding. This study evaluates the association between salivary gland uptake on 1 8 F‐florbetaben PET and cortical amyloid burden and assesses its diagnostic value.

Methods

We retrospectively analyzed 73 patients who underwent 18 F‐florbetaben PET imaging. Salivary gland uptake (SUVR SG ) was measured and compared with the cortical amyloid burden, severity of dementia, and clinical diagnoses (cognitively normal, mild cognitive impairment, and dementia). Diagnostic performance was assessed using receiver operating characteristic (ROC) curve analyses.

Results

The mean SUVR SG was 1.43 ± 0.29, with no significant differences based on the cortical amyloid burden, severity of dementia, or clinical diagnosis. SUVR SG did not correlate with the cortical amyloid burden (ρ = −0.103, p > 0.05). The area under the ROC curve and volume under the ROC surface indicated that SUVR SG had poor diagnostic performance.

Conclusions

Salivary gland uptake on 18 F‐florbetaben PET was not associated with the cortical amyloid burden or clinical stage of AD, and it did not demonstrate diagnostic value. Further research is needed to explore its biological significance and standardization methods.

Subjects

MeSH terms (MEDLINE)

Alzheimer DiseasePositron-Emission TomographyStilbenesAniline CompoundsSalivary GlandsHumansFemaleMaleRetrospective StudiesAgedAged, 80 and overCognitive DysfunctionMiddle AgedRadiopharmaceuticals

Author keywords

Alzheimer's diseasePETsalivary gland

Substances

Stilbenes4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbeneAniline CompoundsRadiopharmaceuticals

Authors and institutions

  • Department of Nuclear Medicine, Korea University Ansan Hospital, Ansan, South Korea.
  • Department of Psychiatry, Korea University Ansan Hospital, Ansan, South Korea.
  • Department of Neurology, Korea University Ansan Hospital, Ansan, South Korea.

Cite

APA

Kwon, H. W., Jung, S., Shin, C., Kim, J. H., & Park, M. H. (2026). Salivary Gland Uptake on 18 F‐Florbetaben PET Did Not Demonstrate Additional Diagnostic Value for Alzheimer's Disease. Brain and Behavior. https://doi.org/10.1002/brb3.71199

Vancouver

Kwon HW, Jung S, Shin C, Kim JH, Park MH. Salivary Gland Uptake on 18 F‐Florbetaben PET Did Not Demonstrate Additional Diagnostic Value for Alzheimer's Disease. Brain and Behavior. 2026. doi:10.1002/brb3.71199

BibTeX
@article{Kwon2026,
  author = {Kwon, Hyun Woo and Jung, Saim and Shin, Cheolmin and Kim, Jong Hun and Park, Moon Ho},
  title = {Salivary Gland Uptake on 18 F‐Florbetaben PET Did Not Demonstrate Additional Diagnostic Value for Alzheimer's Disease},
  journal = {Brain and Behavior},
  year = {2026},
  doi = {10.1002/brb3.71199}
}
Start for free →